Issue

Vol. 66 No. 3: Issue 3

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis

https://doi.org/10.14715/cmb/2020.66.3.6
Qiuji Huang
Department of Neurosurgery, Jiaxiang People's Hospital, Jining 272400, China
Junguo Liu
Zaixun Shi
Department of Neurosurgery, Jiaxiang People's Hospital, Jining 272400, China
Xiuhua Zhu

Corresponding Author(s) : Qiuji Huang

qiujihuang@mail.ru

Cellular and Molecular Biology, Vol. 66 No. 3: Issue 3

Abstract

This study was designed to investigate the expressions and roles of MMP-9 and HMGB1 in peripheral blood of patients with epilepsy and their relationship with the cognitive function and to explore factors affecting the prognosis of epilepsy patients. A total of 127 patients with epilepsy were collected in the study group and 120 healthy subjects receiving a physical examination at the same time were collected in the control group. The MMP-9 and HMGB1 expressions and their diagnostic value for epilepsy were compared between the two groups. The relationship between MMP-9 and HMGB1 expression levels and the clinical-pathological features and the Mini-mental State Evaluation Scale (MMSE) of patients from the study group were also analyzed. The serum levels of MMP-9 and HMGB1 in the study group were significantly higher than those in the control group (P< 0.001), and were greatly decreased after the treatment (P<0.001). The ROC curve showed that MMP-9 and HMGB1 combined detection had a good diagnostic efficiency for epilepsy. MMP-9 was much related to the type and disease duration of epilepsy (P< 0.05). HMGB1 was significantly associated with disease duration, seizure, and previous treatment history of epilepsy (P< 0.050). According to the Pearson correlation coefficient analysis, the expressions of MMP-9 and HMGB1 were negatively correlated with MMSE scores of the study group (P< 0.001). Logistic regression analysis showed that the duration of disease, seizures, MMP-9, and HMGB1 were independent risk factors for the prognosis of epilepsy. The expression levels of MMP-9 and HMGB1 in peripheral blood of patients with epilepsy are significantly increased, and negatively correlated with neurological function scores. They have potential involvement in the occurrence and development of epilepsy, which makes them significant for the diagnosis and treatment of epilepsy in the future.

Keywords

MMP-9 HMGB1 MMS Epilepsy.
Huang, Q., Liu, J., Shi, Z., & Zhu, X. (2020). Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis. Cellular and Molecular Biology, 66(3), 39–47. https://doi.org/10.14715/cmb/2020.66.3.6
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Vezzani A, Fujinami RS, White HS, Preux PM, Blümcke I, Sander JW, Löscher W: Infections, inflammation and epilepsy. Acta Neuropathol 131: 211-234, 2016.
  2. Keezer MR, Sisodiya SM, Sander JW: Comorbidities of epilepsy:current concepts and future perspectives. Lancet Neurol 15: 106-115, 2016.
  3. Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, Pringsheim T, Lorenzetti DL, Jetté N: Prevalence and incidence of epilepsy:a systematic review and meta-analysis of international studies. Neurology 88: 296-303, 2017.
  4. Pitkänen A, Löscher W, Vezzani A, Becker AJ, Simonato M, Lukasiuk K, Gröhn O, Bankstahl JP, Friedman A, Aronica E, et al: Advances in the development of biomarkers for epilepsy. Lancet Neurol 15: 843-856, 2016.
  5. Singh A, Trevick S: The epidemiology of global epilepsy. Neurol Clin 34: 837-847, 2016.
  6. Carmassi C, Corsi M, Bertelloni CA, Carpita B, Gesi C, Pedrinelli V, Massimetti G, Peroni DG, Bonuccelli A, Orsini A, et al: Mothers and fathers of children with epilepsy:gender differences in post-traumatic stress symptoms and correlations with mood spectrum symptoms. Neuropsychiatr Dis Treat 14: 1371-1379, 2018.
  7. Sillanpää M, Schmidt D: Long-term outcome of medically treated epilepsy. Seizure 44:211-216, 2017.
  8. Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, et al: Brivaracetam: Rationale for discovery and preclinical profile of a selective SV 2A ligand for epilepsy treatment. Epilepsia 57: 538-548, 2016.
  9. Brigo F, Igwe S C, Del Felice A: Melatonin as add"on treatment for epilepsy. Cochrane Database Syst Rev 8: CD006967, 2016 .
  10. Amar S, Smith L, Fields GB: Matrix metalloproteinase collagenolysis in health and disease. Biochim Biophys Acta Mol Cell Res 1864: 1940-1951, 2017.
  11. Ma R, Yuan B, Du J, Wang L, Ma L, Liu S, Shu Q, Sun H: Electroacupuncture alleviates nerve injury after cerebra ischemia in rats through inhibiting cell apoptosis and changing the balance of MMP-9/TIMP-1 expression. Neurosci Lett 633: 158-164, 2016.
  12. Wan W, Cao L, Khanabdali R, Kalionis B, Tai X, Xia S: The emerging role of HMGB1 in neuropathic pain:a potential therapeutic target for neuroinflammation. J Immunol Res 2016: 6430423, 2016.
  13. Andersson U, Yang H, Harris H: Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets 22: 263-277, 2018.
  14. Artuso R, Mencarelli MA, Polli R, Sartori S, Ariani F, Pollazzon M, Marozza A, Cilio MR, Specchio N, Vigevano F, et al: Early-onset seizure variant of Rett syndrome: definition of the clinical diagnostic criteria. Brain Dev 32: 17-24, 2010.
  15. Patsalos PN: The epilepsy prescriber's guide to antiepileptic drugs. Cambridge University Press, 2018.
  16. Thompson P, Koorenhof L, Kapur N: Memory rehabilitation for people with epilepsy. In: Epilepsy and Memory. Oxford University Press, Oxford, 425-439, 2012.
  17. Dong Y, Sharma VK, Chan BP, Venketasubramanian N, Teoh HL, Seet RC, Tanicala S, Chan YH, Chen C: The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci 299: 15-18, 2010.
  18. Behr C, Goltzene MA, Kosmalski G, Hirsch E, Ryvlin P: Epidemiology of epilepsy. Rev Neurol (Paris) 172: 27-36, 2016.
  19. Shorvon SD: The etiologic classification of epilepsy. Epilepsia 52: 1052-1057, 2011.
  20. Josephson CB, Jetté N: Psychiatric comorbidities in epilepsy. Int Rev Psychiatry 29: 409-424, 2017.
  21. Bronisz E, Kurkowska-Jastrzć™bska I: Matrix metalloproteinase 9 in epilepsy:the role of neuroinflammation in seizure development. Mediators Inflamm 2016: 7369020, 2016.
  22. Paudel YN, Shaikh MF, Chakraborti A, Kumari Y, Aledo-Serrano í, Aleksovska K, Alvim MKM, Othman I: HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction. Front Neurosci 12: 628, 2018.
  23. Wang QM, Wang H, Li YF, Xie ZY, Ma Y, Yan JJ, Gao YF, Wang ZM, Wang LS: Inhibition of EMMPRIN and MMP-9 expression by epigallocatechin-3-gallate through 67-kDa laminin receptor in PMA-induced macrophages. Cell Physiol Biochem 39: 2308-2319, 2016.
  24. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35: 2726-2733, 2004.
  25. de Vries EE, van den Munckhof B, Braun KP, van Royen-Kerkhof A, de Jager W, Jansen FE: Inflammatory mediators in human epilepsy: a systematic review and meta-analysis. Neurosci Biobehav Rev 63: 177-190, 2016.
  26. Singh V, Roth S, Veltkamp R, Liesz A: HMGB1 as a key mediator of immune mechanisms in ischemic stroke. Antioxid Redox Signal 24: 635-651, 2016.
  27. Antón M, Alén F, Gómez de Heras R, Serrano A, Pavón FJ, Leza JC, Garcí­a-Bueno B, Rodrí­guez de Fonseca F, Orio L: Oleoylethanolamide prevents neuroimmune HMGB1/TLR4/NF"kB danger signaling in rat frontal cortex and depressive"like behavior induced by ethanol binge administration. Addict Biol 22: 724-741, 2017.
  28. Wen X, Han XR, Wang YJ, Wang S, Shen M, Zhang ZF, Fan SH, Shan Q, Wang L, Li MQ, et al: MicroRNA-421 suppresses the apoptosis and autophagy of hippocampal neurons in epilepsy mice model by inhibition of the TLR/MYD88 pathway. J Cell Physiol 233: 7022-7034, 2018.
  29. Ito M, Takahashi H, Yano H, Shimizu YI, Yano Y, Ishizaki Y, Tanaka J, Ishii E, Fukuda M: High mobility group box 1 enhances hyperthermia-induced seizures and secondary epilepsy associated with prolonged hyperthermia-induced seizures in developing rats. Metab Brain Dis 32: 2095-2104, 2017.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 934 Download : 584